Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6538
    +0.0014 (+0.22%)
     

  • OIL

    84.14
    +0.57 (+0.68%)
     

  • GOLD

    2,357.00
    +14.50 (+0.62%)
     

  • Bitcoin AUD

    98,356.13
    +812.63 (+0.83%)
     

  • CMC Crypto 200

    1,385.98
    -10.56 (-0.76%)
     

  • AUD/EUR

    0.6099
    +0.0026 (+0.43%)
     

  • AUD/NZD

    1.0986
    +0.0028 (+0.26%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,118.24
    +39.38 (+0.49%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,052.76
    +135.48 (+0.76%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

NexImmune to Present at the 2021 Barclays Global Healthcare Conference

NexImmune, Inc.
·1-min read

GAITHERSBURG, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will present a company overview at the virtual 2021 Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 10:55 a.m. Eastern time.

The presentation will be accessible via live webcast by visiting https://ir.neximmune.com/investors/events-and-presentations. A replay will be available on the NexImmune website following the presentation.

About NexImmune

NexImmune, based in Gaithersburg, Maryland, is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells to generate a specific, potent and durable immune response that mimics natural biology. For more information, visit www.neximmune.com.

Contacts

Investors:
Chad Rubin
Solebury Trout
646-378-2947
crubin@soleburytrout.com

Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312-961-2502
mikebeyer@sambrown.com